BeiGene Ltd.
| NASDAQ: BGNE | Healthcare / Biotechnology / China |
| 196.64 | +5.26 | +2.75% | Vol 159.12K | 1Y Perf -31.58% |
| Aug 11th, 2022 16:00 DELAYED |
| BID | 180.00 | ASK | 204.00 | ||
| Open | 197.90 | Previous Close | 191.38 | ||
| Pre-Market | - | After-Market | 204.00 | ||
| - - | 7.36 3.74% |
| Target Price | 288.67 | Analyst Rating | Moderate Buy 1.75 | |
| Potential % | 46.80 | Finscreener Ranking | ★★★+ 50.86 | |
| Insiders Trans % 3/6/12 mo. | -/-/-100 | Value Ranking | ★★ 46.98 | |
| Insiders Value % 3/6/12 mo. | -/-/-100 | Growth Ranking | ★★+ 49.77 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 25.44 | Earnings Rating | Strong Buy | |
| Market Cap | 20.41B | Earnings Date | 4th Aug 2022 | |
| Alpha | 0.03 | Standard Deviation | 0.18 | |
| Beta | 0.72 |
Today's Price Range 194.25207.27 | 52W Range 118.18426.56 | 5 Year PE Ratio Range -36.70-17.60 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 1.12% | ||
| 1 Month | 10.06% | ||
| 3 Months | 49.56% | ||
| 6 Months | -2.78% | ||
| 1 Year | -31.58% | ||
| 3 Years | 45.28% | ||
| 5 Years | 176.88% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -37.69 | |||
ROE last 12 Months | -39.61 | |||
ROA (5Y Avg) | -11.13 | |||
ROA last 12 Months | -28.32 | |||
ROC (5Y Avg) | -38.14 | |||
ROC last 12 Months | -34.18 | |||
Return on invested Capital Q | -6.44 | |||
Return on invested Capital Y | -10.65 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 5.20 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -8.80 | ||||
| 3.11 | ||||
| 24.57 | ||||
| 605.70 | ||||
| -11.60 | ||||
| -17.38 | ||||
| 3.14 | ||||
| 56.92 | ||||
| 12.58B | ||||
| Forward PE | -15.64 | |||
| PEG | -0.52 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 4.70 | ||||
| 5.00 | ||||
| 0.04 | ||||
| 0.11 | ||||
| - | ||||
| Leverage Ratio | 1.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -75.60 | ||||
| -222.60 | ||||
| -216.50 | ||||
| -280.90 | ||||
| -86.01 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 727.05M | ||||
| 7.03 | ||||
| 218.50 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2022 | -4.23 | -5.56 | -31.44 |
| Q01 2022 | -4.52 | -4.24 | 6.19 |
| Q04 2021 | -4.79 | -6.16 | -28.60 |
| Q03 2021 | -4.82 | -4.46 | 7.47 |
| Q02 2021 | -3.71 | -5.23 | -40.97 |
| Q01 2021 | -3.35 | 0.69 | 120.60 |
| Q04 2020 | -4.03 | -5.20 | -29.03 |
| Q03 2020 | -4.11 | -4.81 | -17.03 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2022 QR | -4.16 | 9.17 | Positive |
| 9/2022 QR | -3.85 | 14.82 | Positive |
| 12/2022 FY | -15.76 | -0.64 | Negative |
| 12/2023 FY | -12.43 | -0.24 | Negative |
| Next Report Date | - |
| Estimated EPS Next Report | -4.23 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 159.12K |
| Shares Outstanding | 103.82K |
| Shares Float | 91.53M |
| Trades Count | 5.08K |
| Dollar Volume | 31.81M |
| Avg. Volume | 252.61K |
| Avg. Weekly Volume | 225.33K |
| Avg. Monthly Volume | 236.33K |
| Avg. Quarterly Volume | 296.18K |
BeiGene Ltd. (NASDAQ: BGNE) stock closed at 196.64 per share at the end of the most recent trading day (a 2.75% change compared to the prior day closing price) with a volume of 159.12K shares and market capitalization of 20.41B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 5300 people. BeiGene Ltd. CEO is John V. Oyler.
The one-year performance of BeiGene Ltd. stock is -31.58%, while year-to-date (YTD) performance is -27.42%. BGNE stock has a five-year performance of 176.88%. Its 52-week range is between 118.18 and 426.56, which gives BGNE stock a 52-week price range ratio of 25.44%
BeiGene Ltd. currently has a PE ratio of -8.80, a price-to-book (PB) ratio of 3.11, a price-to-sale (PS) ratio of 24.57, a price to cashflow ratio of 605.70, a PEG ratio of 2.32, a ROA of -28.32%, a ROC of -34.18% and a ROE of -39.61%. The company’s profit margin is -86.01%, its EBITDA margin is -216.50%, and its revenue ttm is $727.04 Million , which makes it $7.03 revenue per share.
Of the last four earnings reports from BeiGene Ltd., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-4.23 for the next earnings report. BeiGene Ltd.’s next earnings report date is -.
The consensus rating of Wall Street analysts for BeiGene Ltd. is Moderate Buy (1.75), with a target price of $288.67, which is +46.80% compared to the current price. The earnings rating for BeiGene Ltd. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BeiGene Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BeiGene Ltd. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.89, ATR14 : 12.53, CCI20 : 133.34, Chaikin Money Flow : 0.01, MACD : 6.78, Money Flow Index : 51.58, ROC : 10.91, RSI : 49.71, STOCH (14,3) : 76.99, STOCH RSI : 0.85, UO : 57.70, Williams %R : -23.01), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BeiGene Ltd. in the last 12-months were: John V. Oyler (Sold 347 803 shares of value $10 022 365 ), Lai Wang (Option Excercise at a value of $4 025 737)
BeiGene Ltd.
BeiGene Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1.
CEO: John V. Oyler
Telephone: +1 345 949-4123
Address: c/o Mourant Governance Services (Cayman) Limited, Grand Cayman KY1-1108, , KY
Number of employees: 5 300
TipRanks News for BGNE
Fri, 15 Jul 2022 16:47 GMT BeiGene (BGNE) Gets a Buy Rating from Morgan Stanley
- TipRanks. All rights reserved.Fri, 08 Jul 2022 02:48 GMT BeiGene (BGNE) Receives a Hold from SVB Securities
- TipRanks. All rights reserved.Sat, 09 Apr 2022 03:15 GMT Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE), Eledon Pharmaceuticals (ELDN) and Nurix Therapeutics (NRIX)
- TipRanks. All rights reserved.Mon, 28 Feb 2022 16:35 GMT Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE), LHC Group (LHCG) and Natera (NTRA)
- TipRanks. All rights reserved.Mon, 28 Feb 2022 12:41 GMT Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE), ICU Medical (ICUI) and Universal Health (UHS)
- TipRanks. All rights reserved.Tue, 18 Jan 2022 16:32 GMT BeiGene (BGNE) Receives a Buy from Morgan Stanley
- TipRanks. All rights reserved.
